Melita Marcial-Schuster
Family Medicine · Indianapolis, INNPI 1811961261
Payments from drug & device makers
Across 139 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Novo Nordisk$500
- Lilly USA, LLC$447
- AstraZeneca$253
- Sanofi-aventis U.S. LLC$225
- Biohaven Pharmaceutical Holding Company Ltd.$152
- plus $478 from 10 others
What the payments were for
- Consulting fees$1,20037%
- Food & beverage$2,07363%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 2 | $1,219 |
| Novo Nordisk | 32 | $500 |
| Lilly USA, LLC | 37 | $447 |
| AstraZeneca | 17 | $253 |
| Sanofi-aventis U.S. LLC | 14 | $225 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $152 |
| Amgen | 6 | $117 |
| Pfizer | 7 | $115 |
| Boehringer Ingelheim | 6 | $83 |
| Exact Sciences | 3 | $55 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Grifols USA, LLC | 1 | $18 |
| IBSA Pharma Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
How this compares
$3,273 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 32 | $84,195 |
| JardianceEmpagliflozin | 25 | $44,568 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $9,681 |
| SynthroidLevothyroxine Sodium | 13 | $1,803 |
| Potassium Chloride | 11 | $906 |
| Gabapentin | 30 | $599 |
| Tamsulosin Hcl | 13 | $503 |
| Levothyroxine Sodium | 17 | $449 |
| Eszopiclone | 20 | $321 |
| Tramadol Hcl | 39 | $141 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $134 |
| Alprazolam | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $447 | $84,19532 claims |
| Boehringer IngelheimJardiance | $83 | $44,56825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Indianapolis
- Blair BrengleIndianapolis$10.6M
- Steven SmithIndianapolis$2.5M
- Richard TannerIndianapolis$1.6M
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Jakoda SniderIndianapolis$107K
- Robert ClutterIndianapolis$77K
- Gaylen KeltonIndianapolis$42K
- Daniela LoboIndianapolis$38K
- Haihong MaoIndianapolis$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.